Extracellular PTEN-long Polypeptide for Solid Tumor Treatment

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current understanding of PTEN protein localization and function is limited, as it is primarily considered cytoplasmic or nuclear, with no evidence of extracellular presence, which hinders the development of effective therapeutic strategies for solid tumors.

Innovation Solution

Identification and characterization of a novel protein, PTEN-long, which contains an N-terminal signal peptide and is secreted extracellularly, offering a new avenue for treating solid tumors through administration of its polypeptide or expression vector to inhibit tumor growth, induce apoptosis, and inhibit angiogenesis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If PTEN is considered only cytoplasmic or nuclear, then the understanding of PTEN localization is simple, but therapeutic strategies for solid tumors are limited

Engineering Contradiction:
Improvetherapeutic strategiesVSAvoidPTEN localization information
Core Design Contradiction:
Adaptability or versatilityVSLoss of information

Solution Approach 1:

The patent identifies and characterizes a novel extracellular form of PTEN (PTEN-long) that is distinct from the previously known cytoplasmic and nuclear forms. This segmentation of PTEN into multiple localization forms (cytoplasmic, nuclear, and extracellular) provides more complete information about PTEN distribution, enabling development of targeted therapeutic strategies for solid tumors by exploiting the extracellular localization.

Inventive Principle:
Principle #1Segmentation

2Adaptability or versatility

If PTEN-long with N-terminal signal peptide is identified, then extracellular secretion capability is achieved, but protein structure complexity increases

Engineering Contradiction:
Improvesecretion capabilityVSAvoidprotein structure
Core Design Contradiction:
Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent focuses on extracting and characterizing the N-terminal signal peptide sequence from PTEN-long that confers extracellular secretion capability. By identifying this specific functional element, the invention separates the secretion function from the rest of the PTEN structure, allowing for potential modular applications where the signal peptide can be used to redirect PTEN or PTEN-like proteins to extracellular locations without requiring complete structural redesign.

Inventive Principle:
Principle #2Taking out (Extraction)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

PTEN-long effectively treats solid tumors by inhibiting growth, inducing apoptosis in vascular epithelial cells, and reducing angiogenesis, demonstrating anti-tumor and anti-angiogenic activity, with potential applications in various cancer types.

Implementation Method 1

The PTEN tumor suppressor is a cytoplasmic phosphatase which dephosphorylates the important second messenger phosphatidylinositol 3,4,5-triphosphate

Methodology Applied
Scientific EffectDephosphorylation: Hydrolysis

Implementation Method 2

PTEN-long, which contains an N-terminal signal peptide and which is secreted extracellularly

Methodology Applied
Scientific EffectSignal peptide-mediated translocation:

Data Source

PatentEP2400973B1Identification of extracellular form of PTEN that can be used to treat tumors
Publication Date: 2016.11.30 THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
  • EP2400973B1 patent drawingFigure 1
  • EP2400973B1 patent drawingFigure 2
  • EP2400973B1 patent drawingFigure 3

AI summary

An isolated human phosphatase and tensin homolog long polypeptide (PTEN-long) comprising SEQ ID NO:1, fragments and analogs thereof, nucleic acids encoding such and compositions comprising such are provided. Methods to inhibit angiogenesis in a solid tumor, treat a solid tumor, and inhibit growth of a solid tumor using PTEN-long, fragments and analogs thereof, are provided.